Background Antilaminin 332 mucous membrane pemphigoid (MMP) is an autoimmune subepidermal blistering disease with predominant mucosal involvement and autoantibodies against laminin 332. Malignancies have been associated with this disease; however, no standardized detection system for antilaminin 332 serum antibodies is widely available. Objectives Development of a sensitive and specific assay for the detection of antilaminin 332 antibodies. Methods An indirect immunofluorescence (IF) assay using recombinant laminin 332 was developed and probed with a large number of antilaminin 332 MMP patient sera (n = 93), as well as sera from patients with antilaminin 332-negative MMP (n = 153), bullous pemphigoid (n = 20), pemphigus vulgaris (n = 20) and noninflammatory dermatoses (n = 22), and healthy blood donors (n = 100). Results In the novel IF assay, sensitivities with the laminin 332 heterotrimer and the individual a3, b3 and c2 chains were 77%, 43%, 41% and 13%, respectively, with specificities of 100% for each substrate. The sensitivity for the heterotrimer increased when an anti-IgG4 enriched antitotal IgG conjugate was applied. Antilaminin 332 reactivity paralleled disease activity and was associated with malignancies in 25% of patients with antilaminin 332 MMP. Conclusions The novel IF-based assay will facilitate the serological diagnosis of antilaminin 332 MMP and may help to identify patients at risk of a malignancy.
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What's already known about this topic?
• Antilaminin 332 mucous membrane pemphigoid (MMP) is an autoimmune subepidermal blistering disease with predominant mucosal involvement characterized by antilaminin 332 autoantibodies.
• Malignancies have been associated with this disease, but currently no standardized detection system for antilaminin 332 serum antibodies is widely available.
What does this study add?
• A sensitive and highly specific immunofluorescence assay for the detection of antilaminin 332 autoantibodies using recombinant laminin 332-expressing human cells was developed, which will soon be widely available.
What is the translational message?
• This assay may not only facilitate the diagnosis of antilaminin 332 MMP but may also be valuable to monitor disease activity and identify patients at risk of a malignancy.
Mucous membrane pemphigoid (MMP) is the second most frequent pemphigoid disease. It is characterized by autoantibodies against structural proteins of the dermoepidermal junction and predominant mucosal involvement. [1] [2] [3] [4] MMP mainly affects the oral mucosa, followed by the conjunctival, nasal, anogenital, pharyngeal and, rarely, laryngeal and oesophageal mucosa. In about 20% of patients, additional skin lesions arise. 1, 5, 6 The majority of patients with MMP show autoantibodies against BP180 (type XVII collagen), and reactivity against laminin 332 has been observed in about 20% of patients. [7] [8] [9] Laminin 332, previously known as laminin 5, epiligrin, nicein and kalinin, is a heterotrimeric glycoprotein of epithelial basement membranes composed of a3, b3 and c2 chains. 10, 11 In about 30% of patients with antilaminin 332
MMP, an associated malignancy, mostly solid tumours, has been reported. [12] [13] [14] [15] Therefore, the detection of antilaminin 332 autoantibodies is clinically relevant. Serological differentiation is required, as the clinical presentation between patients with MMP with and without antilaminin 332 reactivity does not differ. By indirect immunofluorescence (IF) on 1 mol L À1 NaCl-split human skin, laminin 332-specific antibodies label the dermal side of the artificial split. 16 This binding pattern is not unique for antilaminin 332 reactivity as it is also observed with autoantibodies against type VII collagen in epidermolysis bullosa acquisita and the p200 protein/laminin c1 in anti-p200/laminin c1 pemphigoid. 17, 18 At present, detection of antilaminin 332 serum antibodies is limited to specialized laboratories and the use of different in-house assays, including immunoprecipitation, enzyme-linked immunosorbent assay (ELISA) and immunoblotting (IB) of native and recombinant forms of laminin 332. 8, 16, [19] [20] [21] [22] In this study, a sensitive and highly specific indirect IF test was developed using recombinant laminin 332 expressed in human HEK293 cells. This assay may facilitate the serological diagnosis of antilaminin 332 MMP and will be available by the end of the year.
Materials and methods

Human sera
Sera from patients with antilaminin 332 MMP used for this study (n = 97) were collected at the dermatology departments in Lübeck (Germany), Kurume (Japan), Reims (France), Rome (Italy) and Dallas (U.S.A.). Diagnosis of antilaminin 332 MMP was based on (i) the clinical phenotype with predominant mucosal lesions, (ii) linear deposits of IgG and/or C3 at the basal membrane zone by direct IF microscopy of a perilesional biopsy and (iii) serum IgG reactivity with laminin 332 by IB with extracellular matrix of cultured human keratinocytes. 16 In addition, 84 patients (87%) had serum antibodies that labelled the dermal side of human salt-split skin by indirect IF microscopy. In 53 patients (55%), further clinical data were available, and in 13 (25%) of these patients a concomitant malignancy was detected.
In five patients, sera were analysed during the course of the disease at between four and seven different time points. Disease activity was scored based on the number of mucosal and skin lesions as described previously:
23 score of 4, > 10 lesions; score of 3, four to 10 lesions; score of 2, one to three lesions; score of 1, complete remission on therapy. The standard MMP Disease Area Index was not applied, as most patients were scored before this index was published. 24 The study was performed following the Declaration of Helsinki and was approved by the ethics committee of the University of Lübeck (12-178) and the corresponding local ethics committees of the centres contributing serum samples to this study. Sera were stored at À20°C or À80°C until use.
Immunofluorescence test
The details of the IF test are described in Appendix S1 (see Supporting Information).
Expression and purification of prokaryotic laminin 332 fragments
Recombinant overlapping N-and C-terminal fragments of each chain containing N-terminal His-tags were produced as detailed in Appendix S1 ( Fig. 1 and Fig. S1a ; see Supporting Information).
Immunoblotting
Recombinant proteins, cell lysates and extracts of extracellular matrix (ECM) of cultured HaCaT cells were fractionated by sodium dodecylsulfate polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and immunoblotted as previously reported. 25 Details are provided in Appendix S1
(see Supporting Information).
BIOCHIP mosaic
BIOCHIPs of recombinantly transfected cells were produced as described previously (Fig. 2) . 26 Briefly, HEK293 transfected with pTriEx-1 constructs of LAMA3, LAMB3 (AE His), LAMC2 (AE His) and the empty plasmid, and cotransfected with LAMA3, LAMB3 and LAMC2 were cultivated on cover glasses. After 48 h, cells were fixed with acetone; cover glasses were cut into millimetre-sized fragments (BIOCHIPs) automatically and glued side by side in the same incubation field on microscopy slides. The six BIOCHIP mosaics within one incubation field were then incubated with individual sera or stored at À196°C until use. To test transfection efficacy, slides were incubated with a laminin a3-reactive MMP serum (1 : 50) and/or anti-His-tag antibody (Merck, Darmstadt, Germany). All human sera were diluted 1 : 10 in phosphate-buffered saline-Tween 20 buffer (EUROIMMUN, Lübeck, Germany) and incubated for 30 min at room temperature. To reveal bound antibodies, a mouse antihuman IgG4 Fc-fluorescein isothiocyanate (FITC) antibody (dilution 1 : 100; clone HP6025; Southern Biotech, Birmingham, AL, U.S.A.) and in parallel an antihuman IgG+IgG4-FITC conjugate (EUROIMMUN) were used. To determine a correlation of autoantibody titres with disease activity, selected patient sera were diluted at a range of 1 : 10 to 1 : 2560.
Statistics
R open-source statistical software (http://www.r-project.org) together with the package 'coin' were used. Statistical procedures for correlation analyses are detailed in Appendix S1 (see Supporting Information).
Results
Reactivity of antilaminin 332 mucous membrane pemphigoid sera with recombinant N-and C-terminal fragments of the three laminin chains
In order to identify the best substrate for antilaminin 332 autoantibody detection, overlapping N-and C-terminal fragments of the three laminin 332 chains (LAMA3, LAMB3 and LAMC2) were expressed in Escherichia coli. The correct migration position of the proteins was visualized by IB ( Fig. S1a ; see Supporting Information). Twenty antilaminin 332 MMP sera were then subjected to IB with the laminin 332 fragments (Table 1) . When the results obtained with LAMA3 N-terminus, LAMA3 C-terminus and LAMB3 N-terminus were combined, all 20 antilaminin 332 MMP sera were recognized ( Table 1) . Five of 40 (13%) normal human sera reacted with various fragments (Table 1) . A comparison of antilaminin 332 MMP sera reactivities with the recombinant fragments and standard detection with IB with ECM is shown in Appendix S1 and Figure S2 (a, b) (see Supporting Information).
Reactivity of antilaminin 332 mucous membrane pemphigoid sera with recombinant full-length proteins of the single laminin 332 chains Due to suboptimal sensitivity and specificity obtained with the prokaryotic fragments, the full-length a3, b3 and c2 chains were then expressed in a eukaryotic system (HEK293 cells) and subjected to IB ( Fig. S1b ; see Supporting Information). As a negative control, HEK293 cells were transfected with the empty pTriEx-1 plasmid. The results obtained by IB of sera from patients with antilaminin 332 MMP (n = 24) and heathy blood donors (n = 20) are shown in Table 2 and Figure S2 (c, d) (see Supporting Information). A high correlation between the anti-a3 chain reactivity detected with ECM and recombinant eukaryotic full-length proteins was seen, and all antilaminin 332 MMP sera showed reactivity with both ECM and the recombinant laminin 332 chains ( Table 2 ). Of note, no reactivity of sera from healthy blood donors with the recombinant proteins, or of antilaminin 332 MMP sera with empty vector-transfected cells was seen ( Table 2) .
Validation of an immunofluorescence cell-based test based on recombinant laminin 332
Laminin 332-expressing HEK293 cells were used as a substrate in indirect IF to test a large panel of IgG4 antilaminin 332 MMP (n = 93) and control sera (n = 315) (Fig. 2) . Forty of 93 (43%) antilaminin 332 MMP sera reacted with the a3 chain, 38 (41%) with the b3 chain and 12 (13%) with the c2 chain of laminin 332 (Table 3 ). The highest sensitivity was observed with the laminin 332 heterotrimer, which recognized 72 of 93 (77%) antilaminin 332 MMP Representative pictures of immunofluorescence microscopy using membrane-bound recombinant laminin a3 (LAMA3), b3 (LAMB3), c2 (LAMC2), the coexpressed chains (a3b3c2; A3, B3, C2) with and without His-tag and empty plasmid (pTriEx; negative control) expressed on HEK293 cells. Blue box, antilaminin 332 mucous membrane pemphigoid (MMP) serum (1 : 10) with laminin a3 reactivity; green box, antilaminin 332 MMP serum (1 : 10) with laminin b3 reactivity; red box, antilaminin 332 MMP serum (1 : 10) with laminin c2 reactivity; yellow box, normal human serum. Values are given as n/N or n/N (%). N, N-terminus; C, C-terminus; HBD, healthy blood donors.
sera. A combination of the single chains did not increase the sensitivity of the test (Table 3 ). The highest sensitivity of 88% was detected in antilaminin 332 MMP sera that reacted by indirect IF with the dermal side of human salt-split skin ( Table 3 ). The distribution of serum reactivity with the different laminin 332 chains is depicted in Figure S3 (see Supporting Information). While the sensitivity with the a3 chain was 76%, and higher by IB with ECM compared with the novel cell-based IF test (43%), more sera recognized the b3 and c2 chains (41% and 13%) in the novel assay compared with IB with ECM (35% and 5%). None of the sera from patients with antilaminin 332-negative MMP (n = 153), bullous pemphigoid (n = 20), pemphigus vulgaris (n = 20) or noninflammatory dermatoses (n = 22), or healthy blood donors (n = 100) were reactive in the cell-based IF test (Table 3) .
Applying an antitotal IgG-FITC conjugate spiked with an anti-IgG4 antibody increased the sensitivity of the novel cellbased IF assay by 7%, while no reactivity was seen with sera from patients with antilaminin 332-negative MMP (n = 100), bullous pemphigoid (n = 20), anti-p200 pemphigoid (n = 20), epidermolysis bullosa acquisita (n = 20) or pemphigus vulgaris (n = 20), or healthy blood donors (n = 250), except for one healthy blood donor serum that reacted with the b3 chain and the heterotrimer.
Correlation of serum antilaminin 332 autoantibodies with disease activity
In five patients with antilaminin 332 MMP, serum was obtained during the course of the disease and subjected to indirect IF on salt-split skin, IB with ECM, and this new antilaminin 332 IF test ( Fig. 3; Figs S4 and S5 ; see Supporting Information). Significant correlations were seen between the disease activity and autoantibody serum levels in all three test systems: antilaminin 332 IF test (stratified Spearman correlation coefficient, q = 0Á7, P = 0Á028 ; Fig. 3) ; IB with ECM (q = 0Á65, P = 0Á005) and indirect IF microscopy on salt-split skin (q = 0Á7, P = 0Á004; Fig. S5 ). We also observed correlations between the different assays, with the highest correlation between the titres obtained by indirect IF microscopy with the BIOCHIP mosaic and human salt-split skin (q = 0Á87, P < 0Á001; Fig. S6 ; see Supporting Information).
Association with malignancy
Of the 97 patients with antilaminin 332 MMP in this study, additional clinical information could be retrieved for 53 Values are given as n/N (%). Values are given as n/N (%). MMP, mucous membrane pemphigoid. patients. In 13 of these patients (25%), a malignancy was present at the time of diagnosis.
Discussion
Laminin 332 is a major component of the anchoring filaments in the skin and mucous membranes, where it mediates cell adhesion via interaction with integrins, syndecans, BP180 (type XVII collagen) and type VII collagen. 11, 27 The importance of laminin 332 for the integrity of skin and mucosa is evident, as mutations in any of the three genes, LAMA3, LAMB3 and LAMC2, cause junctional epidermolysis bullosa. 28 Laminin 332 as the target antigen complex of autoantibodies in patients with MMP was first described by Domloge-Hultsch et al. in 1992. 29 Since then, antilaminin 332 MMP has become a well-recognized entity, and the pathogenic effect of antilaminin 332 antibodies has been shown in different mouse models. 30, 31 Clinically, patients with antilaminin 332 MMP cannot be differentiated from patients with MMP with autoantibodies against the other main target antigen, BP180, although pharyngeal involvement was reported to occur less frequently in the latter patients. 32 Thus shown to be the most sensitive method, followed by IB with ECM of human keratinocytes. Based on this report, IB with ECM of human keratinocytes was chosen as the reference method to compare with our novel IF assay. The ELISA reported by Bekou et al. employing native human laminin 332 revealed a sensitivity of 75%; however, it also detected antilaminin 332 reactivity in 40% of bullous pemphigoid sera. 19 Two subsequent studies found antilaminin 332
IgG in only one of 150 bullous pemphigoid sera. 8, 20 In the present study, antilaminin 332 IgG was detected in only one of 430 control sera including 180 pemphigoid sera. Here, we aimed to overcome two shortcomings of the present detection systems for antilaminin 332 serum IgG: the limited standardization and the lack of availability. In an initial attempt at cost-effectiveness, we addressed the limited standardization and availability. Firstly, we used overlapping prokaryotic fragments of the three laminin 332 chains by IB. Reactivity with a3, b3 and c2 (N-and C-terminal fragments) was found in 95%, 65% and 45% of patients with antilaminin 332 MMP, respectively. In line with this, previous studies also showed predominant anti-a3 reactivity. 32, 35 As six sera (15%) from our 40 healthy blood donors were also reactive, the antilaminin 332 chains were then eukaryotically expressed as full-length proteins and applied to IB. All tested 24 anti-laminin 332 MMP sera were reactive, while sera from 20 healthy blood volunteers were negative. For better standardization and straightforward evaluation, the three full-length chains were expressed both as individual proteins and as the heterotrimer on the surface of HEK293 cells. Subsequently, a large number of antilaminin 332 MMP patient and control sera were probed for antilaminin 332 IgG4 reactivity using BIOCHIP mosaics. The applied BIOCHIP mosaics involved slides with multiple incubation fields each containing several miniature substrates. BIOCHIP mosaics are increasingly being used for the serological diagnosis of autoimmune diseases including autoimmune blistering disorders. 26, [38] [39] [40] [41] [42] By this approach, 43%, 41% and 13% of 93
antilaminin 332 MMP sera reacted with the a3, b3 and c2 chains, respectively, and 77% of sera with the heterotrimer. The lower a3-specific reactivity compared with the smaller cohort may be explained by the different sample size and the composition of tested sera. In line with our results, a previous analysis of sera from Japanese patients with MMP also found about equal anti-a3 and anti-b3 reactivities. 22 When the anti-IgG4 secondary antibody was supplemented with an antitotal IgG conjugate (anti-IgG+IgG4), the sensitivity for detection of autoantibodies to the heterotrimer increased from 77% to 84%, while the specificity remained > 99Á5%. We also demonstrated that serum levels of IgG antilaminin 332 correlated with disease activity in selected patients with antilaminin 332 MMP. Thus, quantitative detection of serum antilaminin 332 IgG levels by the novel IF assays should also prove useful for monitoring of disease activity.
In addition to serological diagnosis and monitoring of disease activity, this novel assay may be helpful to identify patients with MMP at risk of a concomitant malignancy. While some reports described malignancies in about 30% of patients with antilaminin 332 MMP, [12] [13] [14] [15] other authors failed to reveal such an association. 8 This discrepancy may be due to the studied patient population and the applied detection system for antilaminin 332 autoantibodies. In the present study, 25% of patients with antilaminin 332 MMP had a known malignancy at the time of diagnosis. To clarify further the potential association between antilaminin 332 reactivity and malignancies, we propose a prospective study that performs a standardized tumour search in all patients with MMP at the time of diagnosis and during the following 2 years. That study should determine the rate of malignancies in both antilaminin 332-positive and antilaminin 332-negative patients with MMP. The described indirect IF test is a sensitive, specific, highly standardized, easy to conduct and widely available tool for the detection of antilaminin 332 autoantibodies. It will further facilitate the serological diagnosis and management of antilaminin 332 MMP.
